{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:59:01Z","timestamp":1793969941622,"version":"4.8.0"},"reference-count":141,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T00:00:00Z","timestamp":1627171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>The last decade has seen a significant leap in our understanding of the wide range of genetic lesions underpinning acute lymphoblastic leukaemia (ALL). Next generation sequencing has led to the identification of driver mutations with significant implications on prognosis and has defined entities such as BCR-ABL-like ALL, where targeted therapies such as tyrosine kinase inhibitors (TKIs) and JAK inhibitors may play a role in its treatment. In Philadelphia positive ALL, the introduction of TKIs into frontline treatment regimens has already transformed patient outcomes. In B-ALL, agents targeting surface receptors CD19, CD20 and CD22, including monoclonal antibodies, bispecific T cell engagers, antibody drug conjugates and chimeric antigen receptor (CAR) T cells, have shown significant activity but come with unique toxicities and have implications for how treatment is sequenced. Advances in T-ALL have lagged behind those seen in B-ALL. However, agents such as nelarabine, bortezomib and CAR T cell therapy targeting T cell antigens have been examined with promising results seen. As our understanding of disease biology in ALL grows, as does our ability to target pathways such as apoptosis, through BH3 mimetics, chemokines and epigenetic regulators. This review aims to highlight a range of available and emerging targeted therapeutics in ALL, to explore their mechanisms of action and to discuss the current evidence for their use.<\/jats:p>","DOI":"10.3390\/jpm11080715","type":"journal-article","created":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T22:06:21Z","timestamp":1627250781000},"page":"715","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Targeted Therapy in Acute Lymphoblastic Leukaemia"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-5503","authenticated-orcid":false,"given":"Ross","family":"Salvaris","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology, Monash Health, Clayton 3168, Australia"},{"name":"School of Clinical Sciences at Monash Health, Monash University, Clayton 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale Luke","family":"Fedele","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Monash Health, Clayton 3168, Australia"},{"name":"School of Clinical Sciences at Monash Health, Monash University, Clayton 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamaoncol.2017.5305","article-title":"Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome\u2013Negative Acute Lymphoblastic Leukemia","volume":"4","author":"Siegel","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1200\/JCO.2012.48.5292","article-title":"Toward a NOTCH1\/FBXW7\/RAS\/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia study","volume":"31","author":"Trinquand","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Mullighan","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.3324\/haematol.2018.206961","article-title":"NUTM1 is a recurrent fusion gene partner in B-cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2","volume":"104","author":"Hormann","year":"2019","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-18-0236","article-title":"Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia","volume":"79","author":"Comeaux","year":"2019","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1101\/gr.209163.116","article-title":"Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities ofEP300andCREBBP","volume":"27","author":"Qian","year":"2016","journal-title":"Genome Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/cncr.31848","article-title":"BCR\/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?","volume":"125","author":"Chiaretti","year":"2019","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.3324\/haematol.2018.207506","article-title":"How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"104","author":"Frisch","year":"2019","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"13331","DOI":"10.1038\/ncomms13331","article-title":"Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia","volume":"7","author":"Gu","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/leu.2016.80","article-title":"The role of the RAS pathway in iAMP21-ALL","volume":"30","author":"Ryan","year":"2016","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ng.3362","article-title":"Genomics and drug profiling of fatal TCF3-HLF\u2212positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options","volume":"47","author":"Fischer","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1200\/jco.2006.24.18_suppl.6585","article-title":"A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia\/lymphoma (T-ALL) and other leukemias","volume":"24","author":"DeAngelo","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"eaau6246","DOI":"10.1126\/scitranslmed.aau6246","article-title":"Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition","volume":"11","author":"Habets","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V124.21.1.1","article-title":"T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children\u2019s Oncology Group (COG) Study AALL0434","volume":"124","author":"Wood","year":"2014","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early Response\u2013Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study","volume":"35","author":"Bond","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","volume":"348","author":"Guilhot","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/sj.leu.2402770","article-title":"Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)","volume":"16","author":"Wassmann","year":"2002","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2004-04-1389","article-title":"Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia","volume":"104","author":"Towatari","year":"2004","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL\u2013Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","article-title":"Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","article-title":"Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)","volume":"108","author":"Wassmann","year":"2006","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/sj.leu.2404320","article-title":"Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: Results of the GRAALL AFR09 study","volume":"20","author":"Delannoy","year":"2006","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/sj.leu.2403886","article-title":"Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"19","author":"Lee","year":"2005","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3324\/haematol.2014.118588","article-title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: Addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/bjh.12043","article-title":"Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: Comparison of two prospective parallel protocols","volume":"159","author":"Ribera","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"118","author":"Vitale","year":"2011","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib\u2013Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Bassan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A Phase 2 Trial of Ponatinib in Philadelphia Chromosome\u2013Positive Leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.clml.2018.02.010","article-title":"Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia","volume":"18","author":"Jabbour","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study","volume":"10","author":"Cheok","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High Frequency and Poor Outcome of Philadelphia Chromosome\u2013Like Acute Lymphoblastic Leukemia in Adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable kinase gene fusions in high-risk B-ALL: A study from the Children\u2019s Oncology Group","volume":"129","author":"Reshmi","year":"2017","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"key":"ref_43","first-page":"1657","article-title":"Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL","volume":"1","author":"Roberts","year":"2017","journal-title":"Blood Adv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2016-05-707653","article-title":"Potent efficacy of combined PI3K\/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.3324\/haematol.2018.192088","article-title":"Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure","volume":"103","author":"Ding","year":"2018","journal-title":"Haematologica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.3324\/haematol.2013.095372","article-title":"Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion","volume":"98","author":"Lengline","year":"2013","journal-title":"Haematologica"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1200\/JCO.2012.47.6770","article-title":"Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory EBF1-PDGFRB\u2013Positive Acute Lymphoblastic Leukemia","volume":"31","author":"Weston","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/pbc.25327","article-title":"TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP\/PDGFRB translocation","volume":"62","author":"Kobayashi","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.12659\/AJCR.906300","article-title":"Acute Lymphoblastic Leukemia Patient with Variant ATF7IP\/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report","volume":"18","author":"Zhang","year":"2017","journal-title":"Am. J. Case Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/10428194.2020.1842401","article-title":"Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia","volume":"62","author":"Lunghi","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/bloodadvances.2019000769","article-title":"Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement","volume":"4","author":"Nardi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/blood.2020006113","article-title":"Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts","volume":"136","author":"Perner","year":"2020","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: Analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2014-08-596403","article-title":"Monoclonal antibodies in acute lymphoblastic leukemia","volume":"125","author":"Jabbour","year":"2015","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","article-title":"CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: Setting the stage for anti-CD20 directed immunotherapy","volume":"112","author":"Dworzak","year":"2008","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cyto.b.20516","article-title":"Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group","volume":"78","author":"Dworzak","year":"2010","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome\u2013Negative Precursor B-Lineage Acute Lymphoblastic Leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/S2352-3026(20)30144-7","article-title":"Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: A single-arm, phase 2 trial","volume":"7","author":"Jabbour","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/bjh.13764","article-title":"Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive\/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): Potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL","volume":"171","author":"Awasthi","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II Trial of the Anti-CD19 Bispecific T Cell\u2013Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-140766","article-title":"Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R\/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO)","volume":"136","author":"Locatelli","year":"2020","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood-2019-132435","article-title":"A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR\/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents\/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children\u2019s Oncology Group Study AALL1331","volume":"134","author":"Brown","year":"2019","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Dombret","year":"2018","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ejh.13375","article-title":"Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia","volume":"104","author":"Dombret","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.bbmt.2019.04.020","article-title":"Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia","volume":"25","author":"Marks","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-134774","article-title":"A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed\/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study","volume":"136","author":"Brivio","year":"2020","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bjh.14806","article-title":"A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia","volume":"182","author":"Short","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S2352-3026(15)00020-4","article-title":"90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: A phase 1 dose-escalation study","volume":"2","author":"Chevallier","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.3324\/haematol.2014.120220","article-title":"Vincristine, dexamethasone and epratuzumab for older relapsed\/refractory CD22+ B-acute lymphoblastic leukemia patients: A phase II study","volume":"100","author":"Chevallier","year":"2015","journal-title":"Haematologica"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/pbc.25454","article-title":"Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children\u2019s Oncology Group (COG) study ADVL04P2","volume":"62","author":"Raetz","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.12778","article-title":"SWOG S0910: A phase 2 trial of clofarabine\/cytarabine\/epratuzumab for relapsed\/refractory acute lymphocytic leukaemia","volume":"165","author":"Advani","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-139260","article-title":"Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival","volume":"136","author":"Taraseviciute","year":"2020","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1182\/blood-2019-127890","article-title":"Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse\/ Refractory ALL Patients","volume":"134","author":"Tang","year":"2019","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-143474","article-title":"Tandem CD19\/CD22 Dual Targets CAR-T Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study","volume":"136","author":"Cui","year":"2020","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1182\/blood-2018-99-111856","article-title":"Sequential CD19- and CD22-CART Cell Therapies for Relapsed B-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-019-0613-7","article-title":"Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia","volume":"34","author":"Quintarelli","year":"2020","journal-title":"Leukemia"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.3389\/fimmu.2019.03123","article-title":"High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia","volume":"10","author":"Bexte","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/blood-2003-01-0317","article-title":"Mechanisms for T-cell selective cytotoxicity of arabinosylguanine","volume":"102","author":"Rodriguez","year":"2003","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","article-title":"High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation","volume":"118","author":"Basara","year":"2011","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children\u2019s Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","article-title":"Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults with Refractory Hematologic Malignancies","volume":"23","author":"Kurtzberg","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children\u2019s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.24947","article-title":"Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma","volume":"93","author":"Abaza","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood-2020-136873","article-title":"Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial","volume":"136","author":"Maiti","year":"2020","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","article-title":"Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study","volume":"120","author":"Messinger","year":"2012","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: A report from the Children\u2019s Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-134730","article-title":"Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children\u2019s Oncology Group (COG) Trial AALL1231","volume":"136","author":"Teachey","year":"2020","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e000630","DOI":"10.1136\/jitc-2020-000630","article-title":"Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: An implication for anti-CD38 immunotherapy","volume":"8","author":"Tembhare","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Roizenblatt, S., Caba\u00f1as-Pedro, A.C., and Figueiredo, M.S. (2020). Rheumatoid arthritis and sickle cell disease: A potential association. Br. J. Haematol., 191.","DOI":"10.1111\/bjh.16952"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41409-018-0222-5","article-title":"Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia\u2014A worthwhile strategy?","volume":"53","author":"Bonda","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41375-019-0548-z","article-title":"Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell\/CD19\/CD22-negative acute lymphoblastic leukemia","volume":"34","author":"Ofran","year":"2020","journal-title":"Leukemia"},{"key":"ref_113","first-page":"CT052","article-title":"Abstract CT052: Clinical safety and efficacy study of TruUCAR\u2122 GC027: The first-in-human, universal CAR-T therapy for adult relapsed\/refractory T-cell acute lymphoblastic leukemia (r\/r T-ALL)","volume":"80","author":"Wang","year":"2020","journal-title":"Tumor Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Srinivasan","year":"2017","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1200\/JCO.2020.38.15_suppl.3026","article-title":"First-in-human clinical trial of the autologous CD7-CART for relapsed\/refractory ACUTE lymphoblastic leukemia\/lymphoma","volume":"38","author":"Zhang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","article-title":"Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia","volume":"133","author":"Sanchez","year":"2019","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ceb.2005.10.001","article-title":"Life in the balance: How BH3-only proteins induce apoptosis","volume":"17","author":"Willis","year":"2005","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","article-title":"BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia","volume":"111","author":"Schlis","year":"2008","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","article-title":"Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia","volume":"128","author":"Khaw","year":"2016","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2019-126977","article-title":"Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed\/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","volume":"134","author":"Lacayo","year":"2019","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood-2020-134582","article-title":"Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","volume":"136","author":"Rubnitz","year":"2020","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199","volume":"4","author":"Roderick","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia","volume":"20","author":"Jabbour","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01060-y","article-title":"Targeting chemokines for acute lymphoblastic leukemia therapy","volume":"14","author":"Hong","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ccell.2018.07.007","article-title":"Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1\/TLX1-Positive T Cell Acute Lymphoblastic Leukemia","volume":"34","author":"Bempt","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1158\/1535-7163.MCT-17-1123","article-title":"Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL","volume":"17","author":"Bardini","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1078-0432.CCR-14-1290","article-title":"Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL","volume":"21","author":"Stubbs","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/leu.2017.282","article-title":"Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia","volume":"32","author":"Waibel","year":"2018","journal-title":"Leukemia"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1080\/10428194.2016.1263843","article-title":"Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed\/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia","volume":"58","author":"Vey","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3324\/haematol.2018.192906","article-title":"Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia","volume":"104","author":"Cheung","year":"2019","journal-title":"Haematologica"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.2020006996","article-title":"Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia","volume":"137","author":"Demeyer","year":"2021","journal-title":"Blood"},{"key":"ref_133","first-page":"356","article-title":"Genetic variegation of clonal architecture and propagating cells in leukaemia","volume":"469","author":"Anderson","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood-2014-03-563304","article-title":"Identification of CD34+ and CD34\u2212 leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia","volume":"125","author":"Aoki","year":"2015","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ccr.2008.05.015","article-title":"In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties","volume":"14","author":"Hotfilder","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1182\/blood-2010-06-292300","article-title":"Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance","volume":"116","author":"Chiu","year":"2010","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood-2006-06-030445","article-title":"Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia","volume":"109","author":"Cox","year":"2006","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Tamiro, F., Weng, A.P., and Giambra, V. (2021, January 07). Targeting Leukemia-Initiating Cells in Acute Lymphoblastic Leukemia, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/33414170\/.","DOI":"10.1016\/B978-0-12-821310-0.00003-6"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Tan, S.H., Bertulfo, F.C., and Sanda, T. (2017). Leukemia-Initiating Cells in T-Cell Acute Lymphoblastic Leukemia. Front. Oncol., 7.","DOI":"10.3389\/fonc.2017.00218"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children\u2019s Oncology Group","volume":"38","author":"Gupta","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/8\/715\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:34:46Z","timestamp":1760164486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/8\/715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,25]]},"references-count":141,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["jpm11080715"],"URL":"https:\/\/doi.org\/10.3390\/jpm11080715","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,25]]}}}